Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gesine Bug

Showing results (61-70 of 165) with videos related to

Pageof 17
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 18, 2019
Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte InfusionsMichael Merker, Emilia Salzmann-Manrique, Verena Katzki, et al.
Blood|January 22, 2015
FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferationThomas Oellerich, Sebastian Mohr, Jasmin Corso, et al.
Blood|August 3, 2012
Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-Jan M Middeke, Dietrich Beelen, Michael Stadler, et al.
Cancers|February 10, 2024
Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid MalignanciesFelicitas Schulz, Paul Jäger, Johanna Tischer, et al.
Leukemia & Lymphoma|March 22, 2026
Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphomaClara Walter, Michael C Burger, Kai Siebenbrodt, et al.
Frontiers in Immunology|March 21, 2022
Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following TisagenlecleucelAndreas Peinelt, Melanie Bremm, Hermann Kreyenberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 9, 2018
A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter StudyPatrizia Chiusolo, Gesine Bug, Attilio Olivieri, et al.
British Journal of Haematology|September 17, 2013
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemiaCarsten Müller-Tidow, Gesine Bug, Michael Lübbert, et al.
European Journal of Immunology|April 7, 2022
SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccinationAndrea Jarisch, Eliza Wiercinska, Shabnam Daqiq-Mirdad, et al.
International Journal of Cardiology|October 27, 2018
CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mappingJasmin D Haslbauer, Sarah Lindner, Silvia Valbuena-Lopez, et al.
Pageof 17

Showing results (61-70 of 165) with videos related to

Sort By:
Pageof 17
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 18, 2019
Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte InfusionsMichael Merker, Emilia Salzmann-Manrique, Verena Katzki, et al.
Blood|January 22, 2015
FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferationThomas Oellerich, Sebastian Mohr, Jasmin Corso, et al.
Blood|August 3, 2012
Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-Jan M Middeke, Dietrich Beelen, Michael Stadler, et al.
Cancers|February 10, 2024
Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid MalignanciesFelicitas Schulz, Paul Jäger, Johanna Tischer, et al.
Leukemia & Lymphoma|March 22, 2026
Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphomaClara Walter, Michael C Burger, Kai Siebenbrodt, et al.
Frontiers in Immunology|March 21, 2022
Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following TisagenlecleucelAndreas Peinelt, Melanie Bremm, Hermann Kreyenberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 9, 2018
A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter StudyPatrizia Chiusolo, Gesine Bug, Attilio Olivieri, et al.
British Journal of Haematology|September 17, 2013
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemiaCarsten Müller-Tidow, Gesine Bug, Michael Lübbert, et al.
European Journal of Immunology|April 7, 2022
SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccinationAndrea Jarisch, Eliza Wiercinska, Shabnam Daqiq-Mirdad, et al.
International Journal of Cardiology|October 27, 2018
CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mappingJasmin D Haslbauer, Sarah Lindner, Silvia Valbuena-Lopez, et al.
Pageof 17